{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T10:39:41Z","timestamp":1780483181627,"version":"3.54.1"},"reference-count":6,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T00:00:00Z","timestamp":1654560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T00:00:00Z","timestamp":1654560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ir J Med Sci"],"published-print":{"date-parts":[[2023,4]]},"abstract":"Abstract<\/jats:title>\n Background<\/jats:title>\n Calreticulin (CALR<\/jats:italic>) mutations are commonly identified in patients with essential thrombocythaemia or myelofibrosis. CALR<\/jats:italic> type 1 mutations are known to have a higher overall incidence in males but little is known about the risks of mutation subtypes on myelofibrotic change across patient age and sex.<\/jats:p>\n <\/jats:sec>\n Aims<\/jats:title>\n To identify differences in the incidence of myelofibrotic change within subgroups of patients with CALR<\/jats:italic> type 1 mutations.<\/jats:p>\n <\/jats:sec>\n Methods<\/jats:title>\n All patients with a positive CALR<\/jats:italic> exon 9 mutation identified within our unit between February 2016 and September 2020 were reviewed with note taken of patient sex, age at diagnosis, initial MPN diagnosis, and subsequent disease transformation.<\/jats:p>\n <\/jats:sec>\n Results<\/jats:title>\n In our cohort, young male patients with CALR<\/jats:italic> type 1 mutations were shown to be at significantly increased risk of myelofibrosis compared to age matched female patients.<\/jats:p>\n <\/jats:sec>\n Conclusions<\/jats:title>\n Male patients have a worse myeloproliferative neoplasm phenotype than female patients with it occurring at a younger age and being more myelofibrotic in nature. Further investigation is needed into the reasons for this variability.\n<\/jats:p>\n <\/jats:sec>","DOI":"10.1007\/s11845-022-03047-1","type":"journal-article","created":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T18:02:56Z","timestamp":1654624976000},"page":"591-593","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["CALR type 1 mutations are associated with an increased incidence of myelofibrosis in young male patients"],"prefix":"10.1007","volume":"192","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6729-0132","authenticated-orcid":false,"given":"Philip","family":"Weir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Hindley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Catherwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Frances","family":"McMullin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,7]]},"reference":[{"issue":"2","key":"3047_CR1","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/leu.2015.277","volume":"30","author":"D Pietra","year":"2016","unstructured":"Pietra D, Rumi E, Ferretti VV et al (2016) Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms. Leukemia 30(2):431\u2013438","journal-title":"Leukemia"},{"issue":"8","key":"3047_CR2","doi-asserted-by":"publisher","first-page":"E121","DOI":"10.1002\/ajh.23743","volume":"89","author":"A Tefferi","year":"2014","unstructured":"Tefferi A, Wassie EA, Guglielmelli P et al (2014) Type 1 versus type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients. Am J Hematol 89(8):E121\u2013E124","journal-title":"Am J Hematol"},{"issue":"4","key":"3047_CR3","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1159\/000489006","volume":"139","author":"MA Catherwood","year":"2018","unstructured":"Catherwood MA, Graham A, Cuthbert RJG et al (2018) Absence of CALR mutations in idiopathic erythrocytosis patients with low serum erythropoietin levels. Acta Haematol 139(4):217\u2013219","journal-title":"Acta Haematol"},{"issue":"1","key":"3047_CR4","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/leu.2014.270","volume":"29","author":"X Cabagnols","year":"2015","unstructured":"Cabagnols X, Defour JP, Ugo V et al (2015) Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution. Leukemia 29(1):249\u2013252","journal-title":"Leukemia"},{"issue":"3","key":"3047_CR5","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1677\/jme.1.01784","volume":"35","author":"E Horner-Glister","year":"2005","unstructured":"Horner-Glister E, Maleki-Dizaji M, Guerin CJ et al (2005) Influence of oestradiol and tamoxifen on oestrogen receptors-alpha and -beta protein degradation and non-genomic signalling pathways in uterine and breast carcinoma cells. J Mol Endocrinol 35(3):421\u2013432","journal-title":"J Mol Endocrinol"},{"issue":"Supplement 1","key":"3047_CR6","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1182\/blood-2020-134764","volume":"136","author":"C Harrison","year":"2020","unstructured":"Harrison C, Baxter J, Boucher RH et al (2020) Effects of tamoxifen on the mutant allele burden and disease course in patients with myeloproliferative neoplasms - results of the Tamarin Study. Blood 136(Supplement 1):33\u201335","journal-title":"Blood"}],"container-title":["Irish Journal of Medical Science (1971 -)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-022-03047-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11845-022-03047-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-022-03047-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,2]],"date-time":"2023-04-02T17:04:53Z","timestamp":1680455093000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11845-022-03047-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,7]]},"references-count":6,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["3047"],"URL":"https:\/\/doi.org\/10.1007\/s11845-022-03047-1","relation":{},"ISSN":["0021-1265","1863-4362"],"issn-type":[{"value":"0021-1265","type":"print"},{"value":"1863-4362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,7]]},"assertion":[{"value":"31 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}